Skip to Main Content
Yale School of Medicine
YSM Home

INFORMATION FOR

Diseases of the Integumentary System

Evaluation of abrocitinib in the treatment of generalized granuloma annulare

What is the purpose of this trial?

Participants with generalized granuloma annulare will be treated with abrocitinib 200 mg once daily (there is no placebo group). We will evaluate changes in the activity and extent of granuloma annulare as a result of treatment. The treatment duration in 6 months and visits at 0, 1, 3, and 6 months are required.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Ages
    18 years and older
  • Gender
    Both
Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Nicole Olszewski

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

  • Last Updated
    07/23/2024
  • Study HIC
    #2000033312

Contact Information

For more information about this study, including how to volunteer, contact Nicole Olszewski